



Debiotech names Laurent-Dominique Piveteau as CEO

Lausanne, December 1st 2015 – Debiotech of Switzerland announced today having named Laurent-Dominique Piveteau as CEO of the company.

Dr. Frederic Neftel is proud to announce, as part of a growth transition, the nomination of Laurent-Dominique Piveteau as CEO of the company and member of the Executive Committee.

With a successful growth over the recent years, a number of new products under development and several successful partnerships with Fortune 100 companies, Debiotech has decided to organize its operational activities into several layers with Laurent-Dominique Piveteau taking direct responsibility of the company's operational activities as CEO.

“Laurent-Dominique has done an outstanding work over the last 10 years, of which the last year as COO, and will continue to contribute to our company's growth by taking a more operational role as CEO of the company,” says Dr. Frédéric Neftel, President of Debiotech. “His new position will help us prepare the strategic move to continue to lead the Medtech Innovation sector through new challenges and unique product developments which shall contribute to patient's Quality of Life and treatment improvements.”

Dr. Frederic Neftel will continue to assume strategic responsibility as President and, together with his wife Brigitte Neftel, will be leading the Executive Committee and acting as Board Members of the Company.

Laurent-Dominique Piveteau, CEO of Debiotech: “It's a great honor to take this position in a company with such a reputation and such a track record as Debiotech, and I fully appreciate this sign of trust. It is a very exciting mission that I am ready to fulfill, knowing that I can count on an exceptional team of collaborators who have made and will continue to make the success of the company. This new organization will undoubtedly enable us to meet successfully the many objectives ahead.”

About Debiotech

Debiotech has specialized, for over twenty five years, in the research and development of innovative medical devices, with a focus on implantable and external drug delivery systems for the treatment of severe diseases such as diabetes, renal failure, cardiovascular diseases and cancer. The company's products are based on micromechanics and nanotechnologies, as well as novel technologies. Debiotech has over 40 exclusive license agreements with leading companies in medical devices and pharmaceuticals and holds over 500 patents worldwide.

Further information on Debiotech can be found at www.debiotech.com and specific information on JewelPUMP™ at www.jewelpump.com